Introduction. Pharmacoeconomics of Treatment-Resistant Schizophrenia

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The National Consensus Conference on the Pharmacoeconomics of Treatment- Resistant Schizophrenia, held in Dallas, Texas, in October 1997, was convened in response to the very serious impact of schizophrenia on our patients, their families,and their communities, as well as the very high expense of treating this illness. The objective of this conference was to bring together health care administrators, physicians, and others in decision-making positions in health care to develop strategies to improve the care given to persons with schizophrenia in hopes of reducing the overall cost of treating this deadly disease.

The meeting focused primarily on treatment-resistant schizophrenia because this is the most serious form of the disease and because the overall management of this illness is a particularly acute problem.’ ‹